ErbB3 Monoclonal Antibody (2F12) | Invitrogen MA5-12675 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB3 Monoclonal Antibody (2F12)

catalog :

MA5-12675

quantity :

500 µL

price :

US 447.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

2F12

reactivity :

human, mouse, rat, bovine

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, reverse phase protein lysate microarray, proximity ligation assay, blocking or activating experiments

more info or order :

Invitrogen product webpage

citations: 30

Published Application/Species/Sample/Dilution	Reference
western blot; rat; 1:1000; loading ...; fig 5c	Heffernan C, Jain M, Liu T, Kim H, Barretto K, Li H, et al. Nectin-like 4 Complexes with Choline Transporter-like Protein-1 and Regulates Schwann Cell Choline Homeostasis and Lipid Biogenesis in Vitro. J Biol Chem. 2017;292:4484-4498 pubmed publisher
reverse phase protein lysate microarray; human; loading ...; fig 3a	. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher
immunoprecipitation; human western blot; human	Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
proximity ligation assay; human; 1:40	Green A, Barros F, Abdel Fatah T, Moseley P, Nolan C, Durham A, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat. 2014;145:33-44 pubmed publisher
western blot; human; fig 1c	Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst J, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345-55 pubmed publisher
immunoprecipitation; human	Kirkegaard T, Hansen S, Larsen S, Reiter B, Sørensen B, Lykkesfeldt A. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90-100 pubmed publisher
immunocytochemistry; human immunohistochemistry; human; 1:200 western blot; human	Fichter C, Timme S, Braun J, Gudernatsch V, Schöpflin A, Bogatyreva L, et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer. 2014;135:1517-30 pubmed publisher
western blot; human; fig 5	Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer. 2013;109:2714-23 pubmed publisher
western blot; human	Henjes F, Bender C, Von der Heyde S, Braun L, Mannsperger H, Schmidt C, et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis. 2012;1:e16 pubmed publisher
western blot; human	Teixidó C, Mares R, Aracil M, Ramon Y Cajal S, Hernandez Losa J. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines. PLoS ONE. 2013;8:e53645 pubmed publisher
immunocytochemistry; human; 1:100	Recupero D, Daniele L, Marchio C, Molinaro L, Castellano I, Cassoni P, et al. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol. 2013;229:390-9 pubmed publisher
blocking or activating experiments; human; 1:200	Spears M, Taylor K, Munro A, Cunningham C, Mallon E, Twelves C, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat. 2012;132:463-70 pubmed publisher
immunoprecipitation; human western blot; human	Bollig Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux C, Ethier S. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010;70:7862-73 pubmed publisher
western blot; human	Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17:298-310 pubmed publisher
western blot; human	Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat. 2010;122:685-97 pubmed publisher
immunohistochemistry; human	Bachleitner Hofmann T, Sun M, Chen C, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499-508 pubmed publisher
western blot; human; 1:500	Tao R, Maruyama I. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci. 2008;121:3207-17 pubmed publisher
immunocytochemistry; rat western blot; rat	Zscheppang K, Liu W, Volpe M, Nielsen H, Dammann C. ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L429-35 pubmed
immunoprecipitation; human	Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, et al. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. Mol Cancer Res. 2007;5:393-401 pubmed
immunocytochemistry; mouse	Zscheppang K, Korenbaum E, Bueter W, Ramadurai S, Nielsen H, Dammann C. ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr Pulmonol. 2006;41:1205-12 pubmed
western blot; human	Mukohara T, Civiello G, Johnson B, Janne P. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology. 2005;68:500-10 pubmed
	Rau A, Kocher K, Rommel M, Kühl L, Albrecht M, Gotthard H, et al. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. MAbs. 2021;13:1902034 pubmed publisher
	Falkenberg N, Anastasov N, HÃ¶fig I, Bashkueva K, Lindner K, HÃ¶fler H, et al. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. Mol Oncol. 2015;9:282-94 pubmed publisher
	Laux I, Jain A, Singh S, Agus D. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006;94:85-92 pubmed
	Vijapurkar U, Kim M, Koland J. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp Cell Res. 2003;284:291-302 pubmed
	Dimayuga F, Ding Q, Keller J, Marchionni M, Seroogy K, Bruce Keller A. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol. 2003;136:67-74 pubmed
	Hansen M, Vijapurkar U, Koland J, Green S. Reciprocal signaling between spiral ganglion neurons and Schwann cells involves neuregulin and neurotrophins. Hear Res. 2001;161:87-98 pubmed
	Moasser M, Basso A, Averbuch S, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001;61:7184-8 pubmed
	Hellyer N, Kim M, Koland J. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem. 2001;276:42153-61 pubmed
	Gamett D, Greene T, Wagreich A, Kim H, Koland J, Cerione R. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85. J Biol Chem. 1995;270:19022-7 pubmed

image

image 1 :

product information

Product Type :

Antibody

Product Name :

ErbB3 Monoclonal Antibody (2F12)

Catalog # :

MA5-12675

Quantity :

500 µL

Price :

US 447.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Bovine, Human, Mouse, Rat

Applications :

Western Blot: 4 µg/mL

Species :

Bovine, Human, Mouse, Rat

Clone :

2F12

Isotype :

IgG2a, kappa

Storage :

4° C

Description :

ErbB3 (c-erbB-3/HER-3) is a member of the type I family of growth factor receptors and binds to ligands in the heregulin family. ErbB3 is over-expressed in a variety of tumors in the prostate, bladder, breast, stomach, pancreas, and colon. Heregulin and EGF stimulate tyrosine phosphorylation of c-erbB-3 to different extents. The ErbB3 gene is located on the long arm of human chromosome 12 (12q13) and is transcribed into a 6. 2kb mRNA which is translated into a 160/180 kDa glycoprotein. The ErbB3 gene encodes a transmembrane receptor tyrosine kinase due to alternative splicing and forms heterodimers with other EGF receptor family members that have kinase activity. Heterodimerization leads to the activation of pathways that lead to cell proliferation or differentiation. Alternate transcriptional splice variants encoding different isoforms of ErbB3 have been characterized. One ErbB3 isoform lacks the intermembrane region, is secreted outside the cell, and acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.

Immunogen :

Recombinant rat c-erbB-3/HER-3 oncoprotein

Format :

Liquid

Applications w/Dilutions :

Western Blot: 4 µg/mL

Aliases :

avian erythroblastosis oncogene B 3; avian erythroblastosis oncogene B 3 receptor; C76256; c-erbB3; c-erbB-3; C-errB-3; erb-b2 receptor tyrosine kinase 3; ERBB3; Erbb-3; Erbb3r; erbB3-S; glial growth factor receptor; HER3; human epidermal growth factor receptor 3; LCCS2; MDA BF 1; MDA-BF-1; MGC88033; nuc-ErbB3; p180 ErbB3; p180-ErbB3; p45 sErbB3; p45-sErbB3; p85 sErbB3; p85-sErbB3; proto-oncogene-like protein c-ErbB-3; receptor tyrosine kinase; receptor tyrosine-protein kinase erbB-3; receptor tyrosine-protein kinase erbB-3; LOW QUALITY PROTEIN: receptor tyrosine-protein kinase erbB-3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

more info or order :

Invitrogen product webpage